Stopping Preemptive Antiviral Therapy for Hepatitis B Virus Can Be Considered for Patients with Favorable Predictors

Digestive Diseases and Sciences

Volumn 60, Issue 12, 2015, Pages 3794-3800

  Kim, Hyo Jin ^a   Sinn, Dong Hyun ^a   Kim, Nam Jun ^a   Kim, Jung Hee ^a   Kim, Eun ^a   Gwak, Geum Youn ^a   Paik, Yong Han ^a   Choi, Moon Seok ^a   Lee, Joon Hyeok ^a   Koh, Kwang Cheol ^a   Paik, Seung Woon ^a   Yoo, Byung Chul ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Antiviral therapy; Biochemical flare; Cytotoxic chemotherapy; Discontinuation; Hepatitis B virus; Sustained off treatment virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; RITUXIMAB; STEROID; TELBIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; DIGESTIVE SYSTEM CANCER; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HEPATITIS B VIRUS; HODGKIN DISEASE; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; BLOOD; DRUG ADMINISTRATION; GENETICS; HEPATITIS B, CHRONIC; MIDDLE AGED; RISK FACTOR; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VIRAL LOAD;

EID: 84946489403     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3812-8     Document Type: Article

References (18)

1. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol. 2010;25:864–871.
2. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol. 2011;17:1531–1537.
3. Hsu C, Hsiung CA, Su IJ, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–853.
4. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–709.
5. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528.
6. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.
7. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
8. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109–162.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662.
10. Kim KH, Sinn DH, Yun WK, et al. Defining virologic relapse in chronic hepatitis B. Dig Dis Sci. 2011;56:2432–2438.
11. Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521–2530.
12. Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561.
13. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597–1603.
14. Lee HW, Kang W, Ahn SH, et al. Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol. 2014;29:1049–1055.
15. Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ Jr. Hepatitis B reactivation and rituximab in the oncology practice. Oncologist. 2010;15:1113–1121.
16. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011;46:9–16.
17. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–166.
18. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci. 2005;20:816–820.